It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In this work, a novel series of cyanoacetohydrazide linked to 1,2,3-triazoles (9a–n) were designed and synthesized to be evaluated for their anti-α-glucosidase activity, focusing on the fact that α-glucosidase inhibitors have played a significant role in the management of type 2 diabetes mellitus. All synthesized compounds except 9a exhibited excellent inhibitory potential, with IC50 values ranging from 1.00 ± 0.01 to 271.17 ± 0.30 μM when compared to the standard drug acarbose (IC50 = 754.1 ± 0.5 μM). The kinetic binding study indicated that the most active derivatives 9b (IC50 = 1.50 ± 0.01 μM) and 9e (IC50 = 1.00 ± 0.01 μM) behaved as the uncompetitive inhibitors of α-glucosidase with Ki = 0.43 and 0.24 μM, respectively. Moreover, fluorescence measurements were conducted to show conformational changes of the enzyme after binding of the most potent inhibitor (9e). Calculation of standard enthalpy (ΔHm°) and entropy (ΔSm°) values confirmed the construction of hydrophobic interactions between 9e and the enzyme. Also, docking studies indicated desired interactions with important residues of the enzyme which rationalized the in vitro results.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Shiraz University of Medical Sciences, Stem Cells Technology Research Center, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Central Research Laboratory, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
2 Tehran University of Medical Sciences, Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
3 Tehran University of Medical Sciences, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
4 Tehran University of Medical Sciences, Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Tehran University of Medical Sciences, Persian Medicine and Pharmacy Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
5 Tehran University of Medical Sciences, Persian Medicine and Pharmacy Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Tehran University of Medical Sciences, Medicinal Plants Research Center, Faculty of Pharmacy, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)